Andrea Ferrante
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Ferrante has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Boris Calderon
Eli Lilly and Company Indianapolis Indiana USA
2 shared publications - Deven Lemen
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
2 shared publications - Garrett R. Mullins
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
2 shared publications - Heather A. Bullock
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
2 shared publications - Jeff W. Cramer
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
2 shared publications - Justin K. Mack
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, USA
2 shared publications
Latest Publications
- Open Access
- 18 March 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (3) , 75
Correction: Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules
- 18 March 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (3) , 75
Open AccessCorrection: Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules
- 13 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 160
Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules
Formation of anti-drug antibodies (ADA) and, in particular, neutralizing antibodies (NAb), is a major risk to the development of biotherapeutics. Cell-based assays, which can reflect the mechanistic interactions among the drug, target, and NAb, are often most suitable for the detection of NAb. We report the development and validation of cell-based platform assays for a class of incretin molecules. An affinity capture elution step was employed to improve drug tolerance of a cell-based cyclic adenosine monophosphate (cAMP) assay. Assay conditions and procedures, including acid elution, cell density, and TAG labeled cAMP (cAMP-TAG) incubation time and concentration, were thoroughly optimized. Delta percent (Δ%) Neutralization was used to reduce assay variability during validation and sample analysis. This platform method has been applied to several incretin molecules and has demonstrated desired sensitivity, drug tolerance, and robustness.
- 13 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 160
Affinity Capture Elution Coupled with Cell-based Cyclic Adenosine Monophosphate Assay as a Platform Method for Detection of Neutralizing Antibodies to Incretin Molecules
Formation of anti-drug antibodies (ADA) and, in particular, neutralizing antibodies (NAb), is a major risk to the development of biotherapeutics. Cell-based assays, which can reflect the mechanistic interactions among the drug, target, and NAb, are often most suitable for the detection of NAb. We report the development and validation of cell-based platform assays for a class of incretin molecules. An affinity capture elution step was employed to improve drug tolerance of a cell-based cyclic adenosine monophosphate (cAMP) assay. Assay conditions and procedures, including acid elution, cell density, and TAG labeled cAMP (cAMP-TAG) incubation time and concentration, were thoroughly optimized. Delta percent (Δ%) Neutralization was used to reduce assay variability during validation and sample analysis. This platform method has been applied to several incretin molecules and has demonstrated desired sensitivity, drug tolerance, and robustness.